Sunridge International, a pioneering developer of non-invasive as well as safe glaucoma treatment, made a proud announcement of having received consent for the company’s Pneumatic Trabeculoplasty treatment or PNT in China from the SFDA (State Food and Drug Administration).
Sunridge International with its entirely held ancillary, Ophthalmic International, the firm produces vacuum fixation devices and copyrighted design suction rings for treating open angle glaucoma.
G. Richard Smith, chief executive officer of Sunridge International made the pronouncement stating that the SFDA consent marks a significant stride ahead for the firm, which it hopes would be able to provide respite with its PNT glaucoma treatment to scores of Chinese suffering from this eye condition.
Mr. Smith further added that their select distributor company, Beijing Vision World Trading Co, have notified them that they have acquired all the requisite government documents accepting PNT as a medical glaucoma treatment as well as for treating ocular hypertension. He further stated having received marketing acceptance for their gear and non-reusable line of items.
Beijing Vision’s President, Waisheng Yang stated that the SFDA acceptance has been rightfully earned, marking the conclusion of over three years of steady market expansion which has incorporated several clinical studies in privately-run as well as state-run military hospitals. He gave due credit to the persistent efforts of several committed individuals for this accomplishment. Mr. Yang added that they were all set to commence their marketing manoeuvres all over China and becoming accessible to the over ten million Chinese who suffer from glaucoma.
Mr. Smith further mentioned about the commencement of their subsequent phase of marketing program in China alongside favourable reports of having received preliminary orders of thirty units and ten thousand rings which would be placed in hospitals all over China.
PNT is an effectual, risk-free, two-minute-long lasting, non-invasive and economical substitute for treating ocular hypertension and glaucoma which has been created, copy righted and delivered entirely by Ophthalmic International.
